MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
MediPharm Labs (MEDIF) has initiated production of cannabis metered dose inhalers for the EU and UK markets through its partnership with Blackpoint Limited. The product, manufactured under GMP standards, offers a smoke-free, precise dosing solution for cannabis delivery. Expected launch in Q3 2025 follows successful releases in Canadian Adult Use & Wellness and Medical channels, with Australia also targeted.
The agreement with Blackpoint includes exclusive distribution rights and minimum purchase obligations. The European medicinal cannabis market is projected to reach €834 million in 2024. The innovative inhaler provides precise doses of cannabis API, similar to asthma treatments, offering a discreet and familiar delivery method without the stigma or byproducts of smoking or vaping.
MediPharm Labs (MEDIF) ha avviato la produzione di inalatori a dose misurata di cannabis per i mercati UE e UK, grazie alla partnership con Blackpoint Limited. Il prodotto, realizzato secondo gli standard GMP, offre una soluzione di dosaggio precisa e senza fumo per la somministrazione della cannabis. Il lancio è previsto per il terzo trimestre del 2025, dopo il successo nei canali Adult Use & Wellness e Medical in Canada, con l'Australia come mercato target.
L'accordo con Blackpoint prevede diritti di distribuzione esclusivi e obblighi di acquisto minimi. Il mercato europeo della cannabis medicinale è stimato raggiungere i 834 milioni di euro nel 2024. L'inalatore innovativo somministra dosi precise di principio attivo della cannabis, simile ai trattamenti per l'asma, offrendo un metodo discreto e familiare senza lo stigma o i sottoprodotti del fumo o del vaping.
MediPharm Labs (MEDIF) ha iniciado la producción de inhaladores de dosis medida de cannabis para los mercados de la UE y Reino Unido, a través de su asociación con Blackpoint Limited. El producto, fabricado bajo estándares GMP, ofrece una solución de dosificación precisa y libre de humo para la administración de cannabis. El lanzamiento está previsto para el tercer trimestre de 2025, tras exitosas introducciones en los canales de Uso Adulto y Bienestar y Médico en Canadá, con Australia también como mercado objetivo.
El acuerdo con Blackpoint incluye derechos exclusivos de distribución y obligaciones mínimas de compra. Se proyecta que el mercado europeo de cannabis medicinal alcance los 834 millones de euros en 2024. El inhalador innovador proporciona dosis precisas del principio activo de cannabis, similar a los tratamientos para el asma, ofreciendo un método discreto y familiar sin el estigma ni los subproductos del fumar o vapear.
MediPharm Labs (MEDIF)는 Blackpoint Limited와의 파트너십을 통해 EU 및 영국 시장을 위한 대마초 정량 흡입기 생산을 시작했습니다. 이 제품은 GMP 기준에 따라 제조되었으며, 연기 없는 정밀 투여 솔루션을 제공합니다. 출시는 2025년 3분기 예정이며, 캐나다 성인용 및 웰니스, 의료 채널에서 성공적인 출시 후 호주 시장도 목표로 하고 있습니다.
Blackpoint와의 계약에는 독점 유통권과 최소 구매 의무가 포함되어 있습니다. 유럽 의료용 대마초 시장은 2024년에 8억 3,400만 유로에 이를 것으로 예상됩니다. 이 혁신적인 흡입기는 천식 치료제와 유사하게 대마초 활성 성분을 정밀하게 투여하며, 흡연이나 베이핑의 낙인이나 부산물 없이 은밀하고 익숙한 투여 방식을 제공합니다.
MediPharm Labs (MEDIF) a lancé la production d'inhalateurs doseurs de cannabis pour les marchés de l'UE et du Royaume-Uni grâce à son partenariat avec Blackpoint Limited. Ce produit, fabriqué selon les normes GMP, offre une solution de dosage précise et sans fumée pour l'administration du cannabis. Le lancement est prévu au troisième trimestre 2025, après des sorties réussies dans les canaux Usage Adulte & Bien-être et Médical au Canada, avec l'Australie également ciblée.
L'accord avec Blackpoint inclut des droits exclusifs de distribution et des obligations d'achat minimales. Le marché européen du cannabis médical devrait atteindre 834 millions d'euros en 2024. L'inhalateur innovant délivre des doses précises de principe actif du cannabis, similaire aux traitements de l'asthme, offrant une méthode discrète et familière sans la stigmatisation ni les sous-produits du tabagisme ou du vapotage.
MediPharm Labs (MEDIF) hat die Produktion von Cannabis-Dosisinhalatoren für die EU- und UK-Märkte im Rahmen seiner Partnerschaft mit Blackpoint Limited aufgenommen. Das Produkt wird nach GMP-Standards hergestellt und bietet eine rauchfreie, präzise Dosierungslösung für die Cannabisabgabe. Der geplante Markteintritt im dritten Quartal 2025 folgt erfolgreichen Einführungen in den kanadischen Adult Use & Wellness- sowie Medizin-Kanälen, mit Australien als weiterem Zielmarkt.
Die Vereinbarung mit Blackpoint umfasst exklusive Vertriebsrechte und Mindestabnahmeverpflichtungen. Der europäische Markt für medizinisches Cannabis wird für 2024 auf 834 Millionen Euro geschätzt. Der innovative Inhalator liefert präzise Dosen des Cannabis-Wirkstoffs, ähnlich wie bei Asthmabehandlungen, und bietet eine diskrete und vertraute Abgabemethode ohne das Stigma oder Nebenprodukte von Rauchen oder Vapen.
- Expansion into large EU market worth €834 million
- Exclusive distribution agreement with Blackpoint including minimum purchase obligations
- Product already successfully launched in Canadian markets
- GMP certification ensures high-quality manufacturing standards and global market access
- None.
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited (“Blackpoint”), MediPharm’s exclusive sales and distribution partner in those territories.
This discreet and innovative product provides patients with a smoke-free option when seeking fast onset of effects without combustion or heating. The cannabis metered dose inhaler, manufactured by MediPharm Labs under Good Manufacturing Practices (“GMP”), delivers a precise dose of cannabis active pharmaceutical ingredients (API) with GMP-qualified components and excipients.
MediPharm Labs has launched metered dose inhalers in the Canadian Adult Use & Wellness and Medical channels and expects to launch in Australia, the EU and the United Kingdom in Q3 of this year.
Management Commentary:
David Pidduck, CEO of MediPharm Labs, commented, "We’re excited to expand our international portfolio and partner with Blackpoint to bring our innovative cannabis metered dose inhaler to the EU and United Kingdom. This smoke- and vapor-free format supports our mission to advance global access to pharma-grade cannabinoid wellness products. Successfully launching in these markets reflects the strength of our global execution strategy and our ability to manage the complexities of international compliance, logistics, and market access.”
David Martinez, CEO of Blackpoint, added, "Working together with the highly capable team at MediPharm is exciting and we look forward to introducing our novel and much needed metered dose products for the benefit of the growing number of patients across the EU and United Kingdom.”
Additional highlights:
- EU & United Kingdom Exclusive Supply and Distribution: MediPharm Labs is the exclusive supplier and manufacturer of the cannabis metered dose inhaler to Blackpoint and will leverage its relationships and distribution in the EU and the United Kingdom. Prohibition Partners estimated the European medicinal cannabis market to be worth
€834 million in 2024.¹ The agreement with Blackpoint includes minimum purchase obligations to ensure a steady supply of the product in the designated markets. - Innovative Delivery Method: The metered dose inhaler offers a precise and repeatable dose of cannabis API, ensuring consistent and reliable patient outcomes without the stigma, smell or by-products of smoking or vaping.
- GMP Manufacturing: The product is manufactured under stringent GMP standards, ensuring the highest quality and safety for medical use. MediPharm’s multiple GMP certifications and global reach will enable the Company to launch the product internationally.
- Medical Applications: The inhaler is designed for medical applications, providing a discreet, familiar and effective delivery method for patients, similar to the metered dose inhaler format used in asthma treatments.
About MediPharm Labs
MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products utilizing a Good Manufacturing Practices (GMP) certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities for the delivery of pure, trusted, and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021 MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company’s current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm’s reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
For further information, please contact:
MediPharm Labs Investor Relations
Telephone: +1 416.913.7425 ext. 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
Media Contact: John Vincic, Oakstrom Advisors, +1 (647) 402-6375, john@oakstrom.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events, or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events, or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, MediPharm’s access to and unique position in the international medical markets, future growth in Australia, the EU, the United Kingdom and internationally, MediPharm’s timing and ability to launch and distribute its metered dose inhalers in Australia, the EU, the United Kingdom and internationally, MediPharm’s ability to further expand its international portfolio, MediPharm’s ability to leverage its relationships and distribution in the EU and the United Kingdom, any future valuations of the European medicinal cannabis market, and MediPharm’s unique pharma expertise. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political, and social uncertainties; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
¹Prohibition Partners. "The European Cannabis Report: 9th Edition." Prohibition Partners, May 8, 2024.
FAQ
When will MediPharm Labs (MEDIF) launch its cannabis metered dose inhaler in the EU and UK?
What is unique about MediPharm Labs' cannabis metered dose inhaler?
Who is MediPharm Labs' distribution partner for the EU and UK markets?
What is the size of the European medicinal cannabis market?
In which markets has MediPharm Labs already launched its cannabis metered dose inhaler?
